Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 404 participants.
Also called NCT01973231
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 404 participants
- Sponsor
- Registry
-
NCT01973231 -
2012-004984-27
-
- Main results
- Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Czechia, Finland, France, Germany, Hungary, Italy, Latvia, Lithuania, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01973231. Randomized; no masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2015-12-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
- Acronym
- LIRA-LIXI™
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- liraglutide
- Intervention (Drug)
- lixisenatide
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01973231- Content hash
5af075ed44745ec2b965ed2ce5e0576d587fc4cb2150c6ac0f9733a3119ca015